D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 73 Citations 31,321 445 World Ranking 13392 National Ranking 182

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Multiple myeloma

His primary areas of investigation include Multiple myeloma, Internal medicine, Surgery, Bortezomib and Oncology. Maria-Victoria Mateos works in the field of Multiple myeloma, namely Melphalan. His research on Internal medicine often connects related areas such as Gastroenterology.

His Surgery study incorporates themes from Adverse effect and Urology. Maria-Victoria Mateos combines subjects such as Thalidomide and Median follow-up with his study of Bortezomib. The study incorporates disciplines such as Elotuzumab and Daratumumab in addition to Oncology.

His most cited work include:

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. (1547 citations)
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Multiple myeloma, Internal medicine, Oncology, Bortezomib and Lenalidomide. His Multiple myeloma study combines topics from a wide range of disciplines, such as Clinical trial and Minimal residual disease. His Internal medicine research incorporates themes from Gastroenterology and Surgery.

Maria-Victoria Mateos has researched Gastroenterology in several fields, including Progressive disease and Neutropenia. In his study, which falls under the umbrella issue of Oncology, Open label is strongly linked to Refractory Multiple Myeloma. The concepts of his Bortezomib study are interwoven with issues in Proteasome inhibitor, Urology, Adverse effect, Pharmacology and Hazard ratio.

He most often published in these fields:

  • Multiple myeloma (72.64%)
  • Internal medicine (70.83%)
  • Oncology (41.49%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (70.83%)
  • Multiple myeloma (72.64%)
  • Oncology (41.49%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Daratumumab. While the research belongs to areas of Internal medicine, Maria-Victoria Mateos spends his time largely on the problem of Gastroenterology, intersecting his research to questions surrounding Dosing. His Multiple myeloma research is multidisciplinary, incorporating elements of Adverse effect, Disease and Refractory.

His Oncology research includes elements of Newly diagnosed, Clinical trial, Subgroup analysis and Minimal residual disease. His biological study spans a wide range of topics, including Cancer research and Cyclophosphamide. His research investigates the connection between Daratumumab and topics such as Randomized controlled trial that intersect with problems in Regimen.

Between 2019 and 2021, his most popular works were:

  • Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial (93 citations)
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. (62 citations)
  • Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. (53 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Chemotherapy

Maria-Victoria Mateos focuses on Multiple myeloma, Internal medicine, Dexamethasone, Oncology and Daratumumab. His Multiple myeloma research is multidisciplinary, incorporating perspectives in Clinical trial, Disease and Transplantation. His Internal medicine study typically links adjacent topics like Gastroenterology.

His Dexamethasone research incorporates elements of Cancer research and Bortezomib. His Bortezomib research is multidisciplinary, relying on both Melphalan and Intensive care medicine. His work carried out in the field of Oncology brings together such families of science as Venetoclax and Flow cytometry.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

2775 Citations

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)

2229 Citations

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)

1148 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1131 Citations

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka.
The New England Journal of Medicine (2016)

1105 Citations

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Leukemia (2009)

866 Citations

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal.
The Lancet (2016)

702 Citations

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

María-Victoria Mateos;Meletios A. Dimopoulos;Michele Cavo;Kenshi Suzuki.
The New England Journal of Medicine (2017)

599 Citations

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez.
Lancet Oncology (2010)

588 Citations

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos.
Annals of Oncology (2010)

567 Citations

Best Scientists Citing Maria-Victoria Mateos

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 300

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 259

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 244

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 205

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 203

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 200

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 197

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 193

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 175

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 173

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 159

Sagar Lonial

Sagar Lonial

Emory University

Publications: 154

Pieter Sonneveld

Pieter Sonneveld

Erasmus University Rotterdam

Publications: 144

Francis K. Buadi

Francis K. Buadi

Mayo Clinic

Publications: 138

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 137

Michele Cavo

Michele Cavo

University of Bologna

Publications: 136

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.